Hyperinducible expression of the interferon-gamma (IFN-gamma) gene and its suppression in systemic lupus erythematosus (SLE)

被引:21
作者
Gerez, L
Shkolnik, T
Hirschmann, O
Lorber, M
Arad, G
Kaempfer, R
机构
[1] HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOL VIROL,IL-91120 JERUSALEM,ISRAEL
[2] RAMBAM MED CTR,DEPT RHEUMATOL,HAIFA,ISRAEL
[3] NAHARIAYA HOSP,IMMUNOL LAB,NAHARIYA,JAPAN
关键词
systemic lupus erythematosus; interferon-gamma; mRNA; suppression;
D O I
10.1046/j.1365-2249.1997.4471345.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Transient expression of IFN-gamma and IL-2 mRNA and its control by post-transcriptional and suppressive mechanisms were analysed in phytohaemagglutinin-induced peripheral blood mononuclear cells (PBMC) from 47 patients with SLE and 31 age-matched normal donors, using quantitative hybridization with antisense RNA probes. In SLE, basal levels of gene expression did not deviate from those of normal donors, but strongly aberrant patterns were obtained upon induction. The ratio of subjects exhibiting highly inducible IFN-gamma gene expression in their PBMC to those showing moderate or low inducibility was increased five-fold in SLE (P = 0.003). High inducibility was observed for 43% of SLE patients and was equally pronounced in partial remission, mild or active disease. Inducibility of IL-2 mRNA, by contrast, remained similar to that for normal donors. However, regulation of IFN-gamma gene expression differed for mild SLE. Patients with mild disease showing high inducibility of IFN-gamma mRNA in their PBMC not only had the highest frequency of responders, but also the highest extent of an individual response, defined by superinduction of mRNA, to agents that relieve suppression (gamma-irradiation) or post-transcriptional down-regulation (cycloheximide). By contrast, patients with active SLE showing high IFN-gamma mRNA inducibility had normal suppressive capacity as well as posttranscriptional control. Hence, both high inducibility of the IFN-gamma gene and its suppression are relevant to disease. Hyperactivation of the IFN-gamma gene may be alleviated in mild SLE by a vigorous, concomitant activation of post-transcriptional control and of cell-mediated suppression.
引用
收藏
页码:296 / 303
页数:8
相关论文
共 39 条
[1]   TRANSIENT EXPRESSION OF HUMAN INTERLEUKIN-2 AND INTERFERON-GAMMA GENES IS REGULATED BY INTERACTION BETWEEN DISTINCT CELL SUBSETS [J].
ARAD, G ;
KETZINEL, M ;
TAL, C ;
NUSSINOVICH, R ;
DEUTSCH, E ;
SCHLESINGER, M ;
GEREZ, L ;
KAEMPFER, R .
CELLULAR IMMUNOLOGY, 1995, 160 (02) :240-247
[2]   Dual control of human interleukin-2 and interferon-gamma gene expression by histamine: Activation and suppression [J].
Arad, G ;
Nussinovich, R ;
Naamad, M ;
Kaempfer, R .
CELLULAR IMMUNOLOGY, 1996, 170 (01) :149-155
[3]   T-HELPER CELL DYSFUNCTION IN SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) - RELATION TO DISEASE-ACTIVITY [J].
BERMAS, BL ;
PETRI, M ;
GOLDMAN, D ;
MITTLEMAN, B ;
MILLER, MW ;
STOCKS, NI ;
VIA, CS ;
SHEARER, GM .
JOURNAL OF CLINICAL IMMUNOLOGY, 1994, 14 (03) :169-177
[4]  
CAIRNS E, 1985, J IMMUNOL, V135, P3839
[5]   ELEVATED INTERLEUKIN-10 LEVELS IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
CUSH, JJ ;
SPLAWSKI, JB ;
THOMAS, R ;
MCFARLIN, JE ;
SCHULZEKOOPS, H ;
DAVIS, LS ;
FUJITA, K ;
LIPSKY, PE .
ARTHRITIS AND RHEUMATISM, 1995, 38 (01) :96-104
[6]   CONTROL OF BIOLOGICALLY-ACTIVE INTERLEUKIN-2 MESSENGER-RNA FORMATION IN INDUCED HUMAN-LYMPHOCYTES [J].
EFRAT, S ;
KAEMPFER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (09) :2601-2605
[7]  
EFRAT S, 1982, NATURE, V297, P236, DOI 10.1038/297236a0
[8]   SUPERINDUCTION OF HUMAN INTERLEUKIN-2 MESSENGER-RNA BY INHIBITORS OF TRANSLATION [J].
EFRAT, S ;
ZELIG, S ;
YAGEN, B ;
KAEMPFER, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 123 (02) :842-848
[9]   POLYCLONALLY TRIGGERED B-CELLS IN THE PERIPHERAL-BLOOD AND BONE-MARROW OF NORMAL INDIVIDUALS AND IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS AND PRIMARY SJOGRENS SYNDROME [J].
FAUCI, AS ;
MOUTSOPOULOS, HM .
ARTHRITIS AND RHEUMATISM, 1981, 24 (04) :577-584
[10]  
FIORENTINO DF, 1991, J IMMUNOL, V147, P3815